The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis
Abstract
Objective Insulin resistance and nonalcoholic fatty liver disease have been linked to several lipid metabolites in animals, but their role in humans remains unclear. This study examined the relationship of sphingolipids with hepatic and peripheral metabolism in 21 insulin-resistant obese patients without (NAFL-) or with (NAFL+) nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH) and 7 healthy lean individuals undergoing tissue biopsies during bariatric or elective abdominal surgery. Research design and methods Hyperinsulinemic-euglycemic clamps with d-[6,6- 2 H 2 ]glucose were performed to quantify tissue-specific insulin sensitivity. Hepatic oxidative capacity, lipid peroxidation, and the phosphorylated-to-total c-Jun N-terminal kinase (pJNK-to-tJNK) ratio were measured to assess mitochondrial function, oxidative stress, and inflammatory activity. Results Hepatic total ceramides were higher by 50% and 33% in NASH compared with NAFL+ and NAFL-, respectively. Only in NASH were hepatic dihydroceramides (16:0, 22:0, and 24:1) and lactosylceramides increased. Serum total ceramides and dihydroceramides (hepatic dihydroceramides 22:0 and 24:1) correlated negatively with whole-body but not with hepatic insulin sensitivity. Hepatic maximal respiration related positively to serum lactosylceramide subspecies, hepatic sphinganine, and lactosylceramide 14:0. Liver lipid peroxides (total ceramides, sphingomyelin 22:0) and the pJNK-to-tJNK ratio (ceramide 24:0; hexosylceramide…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With increasing hepatic lipid accumulation, the generation of toxic lipid intermediates (diacylglycerols, ceramides) and altered hepatic mitochondrial respiration rates drive hepatic insulin resistance, inflammation and oxidative stress -all of them fueling pro-fibrotic pathways (Fig. 1) [26,27].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [27]
In the citing paper
“Patients with MASH have 20% higher ceramide concentrations compared to healthy individuals.100,102,104,117”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [100]
In the citing paper
“High levels of plasma ceramides are correlated with the severity of MASLD and reflect hepatic ceramide accumulation.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [100]
In the citing paper
“Ceramides are among the most studied lipids because of their lipotoxic activity in several organs and have been reported to be increased in the plasma of patients with MASLD.94,[99], [100], [101], [102],[107], [108], [109],115”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [100]
In the citing paper
“Among ceramides, in a small cohort of seven patients, Apostolopoulou et al.100 showed that total ceramides, as well as lactosyl-, hexosyl-, and dihydro-ceramides were significantly increased in MASH”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [100]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Sphingolipid metabolites in inflammatory disease
Maceyka, M., & Spiegel, S. (2014) · Nature · doi:10.1038/nature13475 · Cited by 1,277 · cited 3×
“HDL-cholesterol (mg/dL) 64 (57, 83)¶,# 44 (35, 54) 35 (33,45) 52 (43, 59)”
BackgroundKoliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Self-citationTilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002 · cited 8×
“The NAFL+ group included one participant with T2D.”
BackgroundMethodInfluentialSelf-citationReceptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
Holland, W. L., Miller, R. A., Wang, Z. V., Sun, K., Barth, B. M., Bui, H. H., Davis, K. E., Bikman, B. T., Halberg, N., Rutkowski, J. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2277 · Cited by 892 · cited 1×
“Rodent studies using a high-fat diet or in leptin-deficientob/obmicehave shown controversial resultsfortherelationshipof hepatic accumulation of ceramides with hepatic insulin sensitivity (26,27).”
BackgroundSelf-citationSunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672 · cited 2×
“Of note, obese people have increased hepatic mitochondrial capacity (10,11), which declines in nonalcoholicsteatohepatitis (NASH)along”
BackgroundHaus, J. M., Kashyap, S. R., Kasumov, T., Zhang, R., Kelly, K. R., DeFronzo, R. A., & Kirwan, J. P. (2009) · Diabetes · doi:10.2337/db08-1228 · Cited by 663
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616
The role of mitochondria in insulin resistance and type 2 diabetes mellitus
Szendroedi, J., Phielix, E., & Roden, M. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.138 · Cited by 600
Self-citationCellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585 · cited 1×
“Liver total ceramides did not relate to whole-body insulin sensitivity, extending previous findings using HOMA-insulin resistanceasasurrogateof insulinresistance (5).”
Background
Cited by
The integrative biology of type 2 diabetes
Roden, M., & Shulman, G. I. (2019) · Nature · doi:10.1038/s41586-019-1797-8 · Cited by 1,167
Self-citationWhy does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
Self-citationThe complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Self-citationTanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“Deletion of SREBP-1a promotes toll-like receptor-4 (TLR4) stimulation, increased inflammatory gene expression via reprogramming the fatty acid production [47], systemic IR, and reduction of the glucose transport [48].”
BackgroundThe Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
A Longitudinal Big Data Approach for Precision Health
Schüssler-Fiorenza Rose, S. M., Contrepois, K., Moneghetti, K. J., Zhou, W., Mishra, T., Mataraso, S., Dagan-Rosenfeld, O., Ganz, A. B., Dunn, J., Hornburg, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0414-6 · Cited by 494
Mitochondrial alterations in fatty liver diseases
Fromenty, B., & Roden, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.020 · Cited by 424
Self-citationMetabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
SpaceM reveals metabolic states of single cells
Rappez, L., Stadler, M., Triana, S., Gathungu, R. M., Ovchinnikova, K., Phapale, P., Heikenwalder, M., & Alexandrov, T. (2021) · Nature Methods · doi:10.1038/s41592-021-01198-0 · Cited by 390
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology · doi:10.1002/hep.31843 · Cited by 379
Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels
Johnson, E. L., Heaver, S. L., Waters, J. L., Kim, B. I., Bretin, A., Goodman, A. L., Gewirtz, A. T., Worgall, T. S., & Ley, R. E. (2020) · Nature Communications · doi:10.1038/s41467-020-16274-w · Cited by 352
Qi, J., Kim, J.-W., Zhou, Z., Lim, C.-W., & Kim, B. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.09.011 · Cited by 338
Lipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
“However, specific ceramides and other sphingolipids were elevated only in obese individuals with NASH, not those with or without steatosis [118,119].”
BackgroundInfluentialSelf-citationNonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Self-citationUnderstanding the mechanisms of reversal of type 2 diabetes
Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30076-2 · Cited by 299
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Xourafa, G., Korbmacher, M., & Roden, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00898-1 · Cited by 274
“…studies in people with class III obesity (BMI ≥40 kg/m 2 , or BMI ≥35 kg/m 2 with an obesity-related health condition) have shown an association between increasing levels of several ceramides and dihydrocera-mides and features of progressive NAFLD such as oxidative stress and inflammation 37,239 .”
BackgroundSelf-citationInsulin resistance and insulin sensitizing agents
Mastrototaro, L., & Roden, M. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154892 · Cited by 254
Self-citationRosqvist, F., Kullberg, J., Ståhlman, M., Cedernaes, J., Heurling, K., Johansson, H.-E., Iggman, D., Wilking, H., Larsson, A., Eriksson, O., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00160 · Cited by 237
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Lim, S., Kim, J.-W., & Targher, G. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.04.008 · Cited by 213
Peng, K.-Y., Watt, M. J., Rensen, S., Greve, J. W., Huynh, K., Jayawardana, K. S., Meikle, P. J., & Meex, R. C. R. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m085613 · Cited by 220
Dasgupta, D., Nakao, Y., Mauer, A. S., Thompson, J. M., Sehrawat, T. S., Liao, C.-Y., Krishnan, A., Lucien, F., Guo, Q., Liu, M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.031 · Cited by 188
Interorgan Metabolic Crosstalk in Human Insulin Resistance
Gancheva, S., Jelenik, T., Álvarez-Hernández, E., & Roden, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00015.2017 · Cited by 192
Self-citationObesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer
Divella, R., Mazzocca, A., Daniele, A., Sabbà, C., & Paradiso, A. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.29599 · Cited by 167
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Self-citationMetabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., Kahl, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 158
“Nevertheless, certain sphingolipid species were recently found to be increased in insulin-resistant NASH and to correlate with hepatic oxidative stress and inflammation [85].”
Self-citationLipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 176
“Hepatic diacylglycerol (DAG) levels have also been correlated with increased insulin resistance, fat accumulation, oxidative stress, and inflammation—factors that are prevalent in MASLD [117,155,156].”
BackgroundThe many secret lives of adipocytes: implications for diabetes
Scherer, P. E. (2018) · Diabetologia · doi:10.1007/s00125-018-4777-x · Cited by 172
Self-citationLipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Nogueira, J. P., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0013 · Cited by 157
Ooi, G. J., Meikle, P. J., Huynh, K., Earnest, A., Roberts, S. K., Kemp, W., Parker, B. L., Brown, W., Burton, P., & Watt, M. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.013 · Cited by 137
Hepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
Contribution of specific ceramides to obesity-associated metabolic diseases
Hammerschmidt, P., & Brüning, J. C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04401-3 · Cited by 142
“Similarly, an increase in total hepatic ceramide content and that of specific dihydroceramide species (C16:0, C22:0, C24:1) was found in patients with NASH compared to those having fatty liver disease without hepatic inflammation [251].”
BackgroundIn Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
“Some sphingolipids, besides being correlated with IR, are also linked to hepatic oxidative stress and inflammation, suggesting their importance in NASH progression (Apostolopoulou et al., 2018).”
BackgroundRoles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 126
“[43] have studied lean control subjects and insulin-resistant obese patients with or without NAFL and NASH.”
BackgroundSomm, E., Montandon, S. A., Loizides-Mangold, U., Gaïa, N., Lazarevic, V., De Vito, C., Perroud, E., Bochaton-Piallat, M.-L., Dibner, C., Schrenzel, J., et al. (2021) · Translational Research · doi:10.1016/j.trsl.2020.07.008 · Cited by 118
“Chronic inflammation in the liver (in particular the rise in TNFa levels) can initiate ceramide production in hepatocytes and, in turn, ceramides can increase cytokine secretion.70 In humans, sphingolipid species also correlate with hepatic inflammation, suggesting a role for these metabolites during progression from…”
BackgroundInfluentialImpact of Lipids on Insulin Resistance: Insights from Human and Animal Studies
Elkanawati, R. Y., Sumiwi, S. A., & Levita, J. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s468147 · Cited by 131
“125 Ceramide is a bioactive sphingolipid produced from intracellular fatty acids and sphingosine.”
BackgroundJiang, M., Li, C., Liu, Q., Wang, A., & Lei, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00665 · Cited by 122
“NAFLD is also defined by the cytotoxic accumulation of lipids, such as ceramide (2, 3).”
Meex, R. C. R., & Blaak, E. E. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900942 · Cited by 124
Role of ceramides in the pathogenesis of diabetes mellitus and its complications
Mandal, N. A., Grambergs, R. C., Mondal, K., Basu, S. K., Tahia, F., & Dagogo-Jack, S. E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107734 · Cited by 117
Mitochondrial oxidative function in NAFLD: Friend or foe?
Shum, M., Ngo, J., Shirihai, O. S., & Liesa, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101134 · Cited by 122
“Higher hepatic ceramide content was also associated with decreased mitochondrial oxidative capacity in human NASH [10].”
BackgroundThe Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines
Field, B. C., Gordillo, R., & Scherer, P. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.569250 · Cited by 117
“Preventing aberrant ceramide deposition can prevent or ameliorate a variety of cardiometabolic pathologies, including insulin resistance, CVD (atherosclerosis, heart failure), and hepatic steatosis (33, 34), as well as mitochondrial dysfunction (Figure 1).”
BackgroundSelf-citationde l’Hortet, A. C., Takeishi, K., Guzman‐Lepe, J., Morita, K., Achreja, A., Popovic, B., Wang, Y., Handa, K., Mittal, A., Meurs, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.017 · Cited by 113
“Furthermore, human iPS-derived fatty liver tissue-iKD-SIRT1 shows significant increase in lipid classes, specifically fatty Acids, phosphocholines, sphingomyelins (Figure 7D) and triglycerides (Figure 7E), which have been previously found to be associated with NASH(Anjani et al., 2015; Apostolopoulou et al., 2018; Pur…”
BackgroundCrosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
Lim, S. K., Taskinen, M., & Borén, J. (2018) · Obesity Reviews · doi:10.1111/obr.12820 · Cited by 111
“Compared with individuals with simple fatty liver, those with NASH had higher levels of sphingolipids, which are associated with oxidative stress, inflammation, and insulin resistance assessed by insulin clamping.(73) In addition, it has been reported that elevated hepatic DAG levels are associated with insulin resist…”
BackgroundRomeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
“72 Increases in hepatic sphingolipids are associated with increased oxidative stress and lipid peroxidation, 73 potentially important causal mediators for MASLD progression.”
Fine particular matter and its constituents in air pollution and gestational diabetes mellitus
Yu, G., Ao, J., Cai, J., Luo, Z., Martin, R. V., van Donkelaar, A., Kan, H., & Zhang, J. (2020) · Environment International · doi:10.1016/j.envint.2020.105880 · Cited by 97
NAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
“Of note, people with NAFLD usually present with elevated serum triglyceride and low-density lipoprotein (LDL)–cholesterol levels [14].”
BackgroundSelf-citationInsulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnae032 · Cited by 90
Self-citationSphingolipid metabolism in non-alcoholic fatty liver diseases
Régnier, M., Polizzi, A., Guillou, H., & Loiseau, N. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.021 · Cited by 94
Guerra, S., & Gastaldelli, A. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.016 · Cited by 81
Ceramide Synthases Are Attractive Drug Targets for Treating Metabolic Diseases
Raichur, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00483 · Cited by 81
Kupriyanova, Y., Zaharia, O., Bobrov, P., Karusheva, Y., Burkart, V., Szendroedi, J., Hwang, J., Roden, M., Roden, M., Al‐Hasani, H., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.030 · Cited by 78
Self-citationLocal and systemic effects of microbiome‐derived metabolites
Spivak, I., Fluhr, L., & Elinav, E. (2022) · EMBO Reports · doi:10.15252/embr.202255664 · Cited by 75
“Sphingolipids (SL) produced by gut bacteria downregulate the host production of SLs in the liver (Johnson et al , 2020), a process linked to metabolic disorders such as insulin resistance and nonalcoholic steatohepatitis (Apostolopoulou et al , 2018).”
The role of adipose tissue dysfunction in hepatic insulin resistance and T2D
Sancar, G., & Birkenfeld, A. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0115 · Cited by 79
Preuss, C., Jeleník, T., Bódis, K. B., Müssig, K., Burkart, V., Szendroedi, J., Roden, M., & Markgraf, D. F. (2019) · Cells · doi:10.3390/cells8030277 · Cited by 76
Self-citationZaharia, O., Straßburger, K., Knebel, B., Kupriyanova, Y., Karusheva, Y., Wolkersdorfer, M. F., Bódis, K. B., Markgraf, D. F., Burkart, V., Hwang, J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0329 · Cited by 74
“such as diacylglycerols, which inhibit proximal insulin signaling (1), or ceramides, which may act via inflammatory pathways (7).”
BackgroundSelf-citationDihydroceramides: their emerging physiological roles and functions in cancer and metabolic diseases
Lachkar, F., Ferré, P., Foufelle, F., & Papaioannou, A. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2020 · Cited by 68
Wigger, D., Gulbins, E., Kleuser, B., & Schumacher, F. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00210 · Cited by 70
Wittenbecher, C., Cuadrat, R. R. C., Johnston, L., Eichelmann, F., Jäger, S., Kuxhaus, O., Prada, M., Fabiola Del Greco, M., Hicks, A. A., Hoffman, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28496-1 · Cited by 66
The role of hepatic lipid composition in obesity‐related metabolic disease
Willis, S. A., Bawden, S., Malaikah, S., Sargeant, J. A., Stensel, D. J., Aithal, G. P., & King, J. A. (2021) · Liver International · doi:10.1111/liv.15059 · Cited by 69
Gutiérrez‐Cuevas, J., Lucano‐Landeros, S., López-Cifuentes, D., Santos, A., & Armendáriz‐Borunda, J. (2022) · Cancers · doi:10.3390/cancers15010023 · Cited by 68
Nakao, Y., Amrollahi, P., Parthasarathy, G., Mauer, A. S., Sehrawat, T. S., Vanderboom, P. M., Nair, K. S., Nakao, K., Allen, A. M., Hu, Y., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102430 · Cited by 63
Zhu, C., Huai, Q., Zhang, X., Dai, H., Li, X., & Wang, H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.78525 · Cited by 68
“NASH dihydroceramides (16:0, 22:0, and 24:1) and lactosylceramides↑ [109]”
BackgroundGuerra, S., Mocciaro, G., & Gastaldelli, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13695 · Cited by 65
“…↓ NAFLD Total DHC, DHC d18:1/18:0, d18:1/22:0, d18:1/24:0, SM d18:0/16:0, PC 36:0 ↑ NASH PC 16:1/20:4, 38:6, PC 15- MHDA/20:4, PE 16:0/20:4, 38:5, PI 38:5 ↓ NASH Apostolopoulou et al. (2018)58 7 CT BMI 25 kg/m2 7 NAFLD BMI 51 kg/m2 7 NASH BMI 56 kg/m2 Liver biopsy Liver Total CER, LactCER 24:1,…”
Diabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Self-citationGancheva, S., Kahl, S., Pesta, D., Mastrototaro, L., Dewidar, B., Strassburger, K., Sabah, E., Esposito, I., Weiß, J., Sarabhai, T., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1758 · Cited by 60
Self-citationSphingolipids Are Depleted in Alcohol-Related Liver Fibrosis
Thiele, M. S., Suvitaival, T., Trôst, K., Kim, M. G., de Zawadzki, A., Kjærgaard, M., Rasmussen, D. N., Lindvig, K. P., Israelsen, M. E., Detlefsen, S., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.023 · Cited by 62
Carlier, A., Phan, F., Szpigel, A., Hajduch, É., Salem, J., Gautheron, J., Goff, W. L., Guérin, M., Lachkar, F., Ratziu, V., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100154 · Cited by 61
“Interestingly, a study withasmall numberofNASHpatientshasshownan increase inhepatic ceramideconcentrationscontrary to theplasmawhere levels were unchanged.(30) Plasma DhCer thus could be a better biomarker than plasma ceramides for hepatic sphingolipid metabolism.”
BackgroundAssociation of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis
Liu, B., Li, Y., Li, Y., Liu, Y., Yan, Y., Luo, A., Ren, H., & She, Q. (2019) · Hepatology International · doi:10.1007/s12072-019-09972-1 · Cited by 56
Bril, F., Barb, D., Lomonaco, R., Lai, J., & Cusi, K. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.018 · Cited by 55
Metabolic and phenotypic changes induced by PFAS exposure in two human hepatocyte cell models
Alijagić, A., Sinisalu, L., Duberg, D., Kotlyar, O., Scherbak, N. N., Engwall, M., Orešič, M., & Hyötyläinen, T. (2024) · Environment International · doi:10.1016/j.envint.2024.108820 · Cited by 56
Cholesterol – the devil you know; ceramide – the devil you don’t
Tippetts, T. S., Holland, W. L., & Summers, S. A. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.001 · Cited by 58
Yu, X.-D., & Wang, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115157 · Cited by 56
Chen, J., Liang, B., Bian, D., Luo, Y., Yang, J., Li, Z., Zhuang, Z., Zang, S.-F., & Shi, J.-P. (2019) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2019.08.111 · Cited by 46
Dellinger, R. W., Holmes, H. E., Hu-Seliger, T. T., Butt, R. W., Harrison, S. A., Mozaffarian, D., Chen, O., & Guarente, L. (2022) · Hepatology · doi:10.1002/hep.32778 · Cited by 55
Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications
Hammad, S. M., & Lopes-Virella, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814015 · Cited by 56
“Subjects with type 2 diabetes may have a normal BMI (body mass index) and in these non-obese individuals, the pathophysiology of type 2 diabetes remains poorly understood.”
InfluentialImpact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 54
Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2
Aji, G., Huang, Y., Ng, M. L., Wang, W., Lan, T., Li, M., Li, Y., Chen, Q., Li, R., Yan, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007856117 · Cited by 53
“However, compared to other tissues, the liver appears to possess a distinct subset of sphingolipid metabolites associated with insulin resistance (36, 37).”
BackgroundLi, D., Zhao, D., Du, J., Dong, S., Al‐Dhamin, Z., Yuan, X., Li, W., Du, H., Zhao, W. T., Cui, L., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117678 · Cited by 50
The role of dihydrosphingolipids in disease
Magaye, R., Savira, F., Hua, Y., Kelly, D. J., Reid, C. M., Flynn, B. L., Liew, D., & Wang, B. H. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2984-8 · Cited by 50
Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity
Seitz, S., Kwon, Y., Hartleben, G., Jülg, J., Sekar, R., Krahmer, N., Najafi, B., Loft, A., Gancheva, S., Stemmer, K., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0124-x · Cited by 50
Self-citationIshay, Y., Kolben, Y., Kessler, A., & Ilan, Y. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00186.2021 · Cited by 47
Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502978122 · Cited by 46
Self-citationMa, Z., Xu, C., Kang, X., Zhang, S., Li, H., Tao, L., Zheng, D., Guo, X., & Yang, X. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02296-x · Cited by 48
Ai, Z.-L., Zhang, X., Ge, W., Zhong, Y., Wang, H.-Y., Zuo, Z.-Y., & Liu, D. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i43.6131 · Cited by 45
NIRANJAN, S., Phillips, B. E., & Giannoukakis, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1193373 · Cited by 51
“A number of studies in humans revealed elevated intra-hepatic FFA concentrations concurrent with hepatic oxidative stress and inflammation (19).”
BackgroundVelázquez, A. M., Roglans, N., Bentanachs, R., Gené, M., Sala‐Vila, A., Lázaro, I., Rodríguez-Morató, J., Sánchez, R. M., Laguna, J. C., & Alegret, M. (2020) · Nutrients · doi:10.3390/nu12113240 · Cited by 47
“However, we found that the hepatic levels of most ceramide species were not increased by the diet, which could be attributed to the absence of inflammation, as liver ceramides were reported to be increased in NASH, but not in simple steatosis in humans [26].”
BackgroundNeutral sphingomyelinase‐2 and cardiometabolic diseases
Sindhu, S. T. A. K., Leung, Y. H., Arefanian, H., Madiraju, S. R. M., Al‐Mulla, F., Ahmad, R., & Prentki, M. (2021) · Obesity Reviews · doi:10.1111/obr.13248 · Cited by 48
“Either whole body or liver-specific ablation of dihydroceramide desaturase-1 (DES1), which conducts the final step in de novo synthesis of cer- amide from dihydroceramide, was shown to decrease ceramide/ dihydroceramide ratios in tissues and serum and to prevent dietinduced insulin resistance and hepatic steatosis in…”
ResultSomvanshi, P. R., Mellon, S. H., Flory, J. D., Abu-Amara, D., PTSD Systems Biology Consortium;, Wolkowitz, O. M., Yehuda, R., Jett, M., Hood, L., Marmar, C., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00065.2019 · Cited by 43
Circadian rhythm of lipid metabolism
Sinturel, F., Spaleniak, W., & Dibner, C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210508 · Cited by 46
Luo, X., Wang, K., & Jiang, C. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.020 · Cited by 44
Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes
Lopes-Virella, M. F., Baker, N. L., Hunt, K. J., Hammad, S. M., Arthur, J. M., Virella, G., & Klein, R. L. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.03.005 · Cited by 43
Chen, J., Xu, L., Zhang, X.-Q., Liu, X., Zhang, Z., Zhu, Q., Liu, J.-Y., Iqbal, M. O., Ding, N., Shao, C., et al. (2023) · Marine Life Science & Technology · doi:10.1007/s42995-023-00168-z · Cited by 40
“Studies have shown that the most important feature of the pathogenesis of NASH is driven by fibrosis, which is a complex process caused by chronic inflammatory states associated with oxidative stress, hepatic steatosis, insulin resistance, and obesity (Apostolopoulou et al. 2018; Bril et al. 2017; Gancheva et al. 2018…”
BackgroundDraijer, L. G., Froon-Torenstra, D., van Weeghel, M., Vaz, F. M., Bohte, A. E., Holleboom, A. G., Benninga, M. A., & Koot, B. G. P. (2020) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002875 · Cited by 43
“Similar to our study, increased sphingomyelin species in both liver and serum in patients with NAFLD were also found in the study of Apostolopoulou et al (21) who analyzed 21 adults with obesity.”
Ziegler, D., Strom, A., Straßburger, K., Knebel, B., Bönhof, G. J., Kotzka, J., Szendroedi, J., Roden, M., & for the German Diabetes Study group (2020) · Diabetologia · doi:10.1007/s00125-020-05310-5 · Cited by 40
Self-citationCirculating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
Mah, M., Febbraio, M. A., & Turpin-Nolan, S. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.684448 · Cited by 41
Nonalcoholic fatty liver disease and insulin resistance in children
Song, K., Kim, H.-S., & Chae, H. W. (2023) · Korean Journal of Pediatrics · doi:10.3345/cep.2022.01312 · Cited by 41
Johnson, K. A., Endapally, S., Vazquez, D. C., Infante, R. E., & Radhakrishnan, A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010393 · Cited by 39
“Mass spectrometry analysis of sphingomyelin was performed as described previously (41) using a Nexera X2 UHPLC system coupled to a Shimadzu LCMS-8050 triple quadrupole mass spectrometer operating the dual ion source in electrospray negative mode.”
Method
Metadata
- Authors
- Apostolopoulou, M., Gordillo, R., Koliaki, C., Gancheva, S., Jelenik, T., De Filippo, E., Herder, C., Markgraf, D., Jankowiak, F., Esposito, I., Schlensak, M., Scherer, P. E., & Roden, M.
- Affiliations
- Deutsches Diabetes-Zentrum e.V. (DE)
- The University of Texas Southwestern Medical Center (US)
- Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany
- Heinrich Heine University Düsseldorf (DE)
- Institute of Pathology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
- Corresponding author
- Roden, Michael
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-03-30
- Volume
- 41
- Issue
- 6
- Pages
- 1235-1243
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2794512033
- Cited by
- 284
- References
- 37
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 41 · 2023: 33 · 2022: 46 · 2021: 35 · 2020: 50 · 2019: 31 · 2018: 10
- FWCI
- 24.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Research of the State of North Rhine-Westfalia
- German Federal Ministry of Health
- Federal Ministry for Research (BMBF) to the German Center for Diabetes Research
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, sphingolipids, ceramide, dihydroceramide, lactosylceramide, sphinganine, sphingomyelin, insulin resistance, hepatic insulin sensitivity, oxidative stress, lipid peroxidation, c-Jun N-terminal kinase, inflammation, mitochondrial function, obesity
- MeSH terms
- Adult, Animals, Female, Humans, Inflammation, Insulin Resistance, Liver, Male, Middle Aged, Obesity, Oxidation-Reduction, Prospective Studies, Sphingolipids, Lipid Peroxidation, Glucose Clamp Technique, Oxidative Stress, Disease Progression, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.